Langerhans islet transplantation: Early results have been promising with in
sulin production in all cases two years after transplantation. These encour
aging results have been obtained with a specifically designed protocol for
islet harvesting, immunosuppression and transplantation of a large quantity
of islets from several donors.
Early immunosuppression: Since diabetes mellitus type 1 is an autoimmune di
sease, immunosuppression could be a most interesting etiopathological solut
ion. Results obtained both in mouse models and in humans given monoclonal h
umanized anti-lymphocyte T antibodies (hOKT3 gamma 1) during th first 6 wee
ks following diagnosis have been quite encouraging.
Two approaches to gene therapy: For the first, the goal is to improve the t
ransplantation technique by isolating the islets in vitro in an attempt to
improve their function via ex vivo transfection of different genes. The sec
ond approach aims at treatment of the complications of diabetes, particular
ly lower limb arteritis and coronary artery disease. Here the vector is an
adenovirus carrying a gene coding for VEGF, a growth factor with proangioge
nic action.